Chlorthalidone is indicated for: Management of hypertension (high blood pressure). Adjunctive therapy in edema associated with: Congestive heart failure,Hepatic cirrhosis,Corticosteroid and estrogen therapy.

Chlorthalidone is a thiazide-like diuretic with antihypertensive properties, primarily used in the treatment of high blood pressure. It can be administered alone or in combination with other antihypertensive medications. It is also used as an adjunct therapy for edema associated with renal disease, mild to moderate congestive heart failure (functional class II and III) when the glomerular filtration rate exceeds 30 ml/min, ascites due to liver cirrhosis in stable patients, as well as edema related to estrogen or corticosteroid therapy.

Chlorthalidone works by inhibiting the reabsorption of sodium and chloride in the distal renal tubules, leading to increased excretion of water. The increased urine output also promotes potassium loss. Although detailed data on its absorption are limited, its long elimination half-life and clinical use classify it as a long-acting thiazide-type diuretic. Longer-acting agents such as chlorthalidone may cause greater potassium loss.

Despite being a relatively mild diuretic, its effect becomes significantly stronger when combined with loop diuretics, as these increase the amount of sodium chloride delivered to the distal tubules.

The initial blood pressure–lowering effect is mainly due to reduction in blood volume, while the long-term effect is associated with decreased peripheral vascular resistance through mechanisms that are not fully understood. A high salt intake may reduce or reverse its antihypertensive effect.

After absorption, most of the drug is eliminated through the kidneys, with an average elimination half-life of approximately 50 hours. A smaller portion is metabolized and excreted via the liver into bile. Within about 120 hours, nearly 70% of the administered dose is excreted through urine and feces, largely in unchanged form.

Therapy should be initiated with the lowest possible dose, and be titrated thereafter to gain maximum therapeutic benefit while keeping side effects to a minimum (e.g. determine the minimum effective maintenance dose for each patient). A single dose daily or every other day is given in the morning with food is recommended.

Hypertension: Usual adult dose is 25 to 50 mg daily. The clinically useful dosage range is 12.5 to 50 mg daily. Doses greater than 50 mg per day increase metabolic complications and are rarely of therapeutic benefit. For a given dose, the full effect is reached after 3 to 4 weeks. If the decrease in blood pressure obtained using doses of 25 or 50 mg/day proves inadequate, combined treatment with other antihypertensive drugs (such as beta-blockers and ACE inhibitors) is recommended. When adding an ACE inhibitor to calcium channel blocker alone is to be reduced or discontinued.

Edema of Specific Origin: The lowest effective dose is to be identified by titration. Maintenance doses should not exceed 50 mg/day and should be administered over limited periods only. The dosage should be individually adapted to the clinical picture and patient response. For long-term therapy, the lowest possible dosage sufficient to maintain an optimal effect should be employed; this applies particularly to elderly patients.

The therapeutic effect of Chlorthalidone occurs even without salt restriction and is well sustained during continued use.

The elderly: This is a suitable drug for treating hypertension in the elderly, in particular systolic hypertension. Dose of 50 mg daily, or less, should be used to avoid hypovolemia and hypokalemia.

In patients with liver impairment or progressive liver disease, even small changes in fluid, electrolyte balance, or serum ammonia may trigger hepatic coma; therefore, caution is required. In postsympathectomy patients, thiazide diuretics should be started carefully as their blood pressure–lowering effect may be increased. Careful dose adjustment is also needed in patients with severe coronary or cerebral atherosclerosis.

Chlorthalidone may enhance the effects of antihypertensive agents such as guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, and ACE inhibitors. It may also increase the action of curare-like muscle relaxants.

Hypokalemia or hypomagnesemia caused by thiazides may increase the risk of digitalis-induced cardiac arrhythmias. Corticosteroids, ACTH, and amphotericin may further increase potassium loss. Chlorthalidone may alter glucose tolerance, requiring adjustment of insulin or oral antidiabetic drug doses.

Non-steroidal anti-inflammatory drugs such as indomethacin may reduce the diuretic and antihypertensive effects and may worsen kidney function in susceptible individuals. Thiazides may increase sensitivity to curare derivatives and ganglionic blockers.

Co-administration with allopurinol may increase hypersensitivity reactions, while use with amantadine may increase adverse effects. When used with anticancer drugs such as cyclophosphamide or methotrexate, reduced excretion and increased bone marrow suppression may occur.

Anticholinergic drugs may increase chlorthalidone absorption, whereas cholestyramine may reduce its absorption. Vitamin D and calcium salts may increase calcium levels in the blood. Cyclosporin may increase the risk of gout and hyperuricemia. Diazoxide may have enhanced hyperglycemic effects when used together.

Chlorthalidone should not be used in patients with anuria, severe renal failure with creatinine clearance below 30 mL/min, severe liver failure, persistent hypokalemia, hyponatremia, hypercalcemia, or symptomatic hyperuricemia such as gout. It is also contraindicated in patients with hypersensitivity to chlorthalidone or other sulfonamide derivatives.

Caution is required in patients with kidney or liver disease, and regular monitoring of blood urea nitrogen and serum creatinine is recommended. Treatment should be stopped if these values rise significantly. The drug may become ineffective when the glomerular filtration rate falls below 30 mL/min, in which case loop diuretics may be more appropriate.

Electrolyte imbalance is dose-dependent and requires monitoring. Serum potassium should be checked at the start of therapy and periodically thereafter. Conditions such as vomiting, diarrhea, malnutrition, kidney dysfunction, liver disease, or use of corticosteroids may affect potassium balance.

Chlorthalidone may commonly cause hypokalemia, increased uric acid levels, and elevated blood lipids, especially at higher doses. It may occasionally lead to low sodium or magnesium levels and increased blood glucose. Rarely, it may cause high calcium levels, glycosuria, worsening diabetes, or gout.

Skin reactions such as rash or urticaria may occur occasionally, while photosensitivity is rare. Liver-related effects such as cholestasis or jaundice are uncommon. Cardiovascular effects may include postural hypotension and, rarely, arrhythmias. Nervous system effects such as dizziness, slowed thinking, and reduced reaction time may also occur.

Chlorthalidone may reduce placental blood flow and is not recommended for treating hypertension in pregnancy. It should be avoided during pregnancy, especially in the first trimester, unless absolutely necessary and no safer alternatives are available.

The drug passes into breast milk, reaching about 4% of maternal blood levels, and therefore its use during breastfeeding is not recommended.

Renal impairment: Chlorthalidone dosage should be reduced in moderate renal failure (every 24 or 48 hours). It should not be used in advanced renal failure.

Liver disease: There is a risk of precipitating hepatic encephalopathy in patients with liver cirrhosis and ascites.

Use in pregnancy: It is better to avoid chlorthalidone as it crosses the placenta.

Use in lactation: In lactating mothers, a significant amount of chlorthalidone enters breast milk. Like other long-acting thiazides, it can suppress lactation. Chlorthalidone should not be prescribed for lactating mothers.

Symptoms of overdose may include nausea, weakness, dizziness, and electrolyte imbalance. There is no specific antidote. Management includes gastric lavage and supportive care, such as intravenous fluids with electrolytes when needed. Careful monitoring is essential.

Thiazide diuretics & related drugs

Keep below 30°C ,Protect from light and moisture,Keep out of the reach of children